Victoria Socha

DocwireNews

Studies have established metabolic acidosis as a risk factor for progression of chronic kidney disease (CKD). There are few data on the association between metabolic acidosis and cardiovascular disease in patients with CKD. Nancy L. Reaven, MA, and colleagues conducted a longitudinal observational study to examine the association of metabolic acidosis and adverse cardiovascular outcomes as well as the role of metabolic acidosis as an independent predictor of cardiovascular outcomes in patients with pre-dialysis CKD. Results of the study were reported during a poster session at Kidney Week 2019 in a poster titled Association of Metabolic Acidosis with Adverse Cardiovascular Outcomes in Patients with CKD.
The researchers utilized de-identified 2001-2017 electronic medical records (Optum® EMR) to identify patients with CKD stages 3-5. Inclusion criteria were more than two consistent serum bicarbonate values 28 to 365 days apart, more than three estimated glomerular filtration rate (eGFR) values &gt;10 and &lt;60 mL/min/1.73 m2, and two or more years of post-index data (or until death). Follow up continued for up to 10 years for evidence of new onset heart failure.
Patients with metabolic acidosis and those with normal serum bicarbonate levels were defined by two serum bicarbonate values between 12 and &lt;22 mEq/L and 22 to 29 mEq/L, respectively. Potential confounders, including age, sex, race, eGFR, diabetes, hypertension, heart failure, coronary artery disease, peripheral vascular disease, hemoglobin, and serum albumin, were examined using Cox proportional hazards models.
The study included 51,558 patients. At 2 years, the incidence of adverse cardiovascular events was significantly higher among the patients in the metabolic acidosis group compared with those with normal serum bicarbonate levels: heart failure, 29.8% vs 22.8%, P&lt;.001; stroke, 19.5% vs 17.2%, P&lt;.001; and myocardial infarction (MI), 17.2% vs 12.3%, P&lt;.0001, respectively.
During follow-up, there was an independent association between serum bicarbonate and adverse cardiovascular outcomes. The hazard ratios per 1 mEq/L change were: new onset heart  failure, 0.976, 95% confidence interval [CI], 0.971-0.981; stroke, 0.979; 95% CI, 0.973-0.985; and MI, 0.964; 95% CI, 0.958-0.970, respectively.
“In this longitudinal analysis of &gt;51,000 non-dialysis CKD patients followed for up to 10 years, serum bicarbonate levels below 22 mEq/L were associated with increased incidence of major adverse cardiovascular events independent of age, comorbid conditions, and kidney function. Studies evaluating the mechanisms of these associations are needed,” the researchers said.
Source: Reaven NL, Funk SE, Mathur VS, Tangri N. Association of metabolic acidosis with adverse cardiovascular outcomes in patients with CKD. Abstract of a poster presented at the American Society of Nephrology Kidney Week 2019 (Abstract TH-PO693), November 7, 2019, Washington, DC.

Laura Litwin

Adding Amivantamab to Chemotherapy Shows OS Benefit for Certain Patients With NSCLC

EGFR+ NSCLC

Rob Dillard

Study Uncovers Relationship Between Total Serum Calcium and Melanoma

Melanoma

Richard S. Finn, MD

Adam Yopp, MD

IMbrave050 Trial Design: Adjuvant Therapy for Early-Stage Hepatocellular Carcinoma

Liver Cancer

Latest News

Metabolic Acidosis Predictor of Adverse Cardiovascular Outcomes

National Kidney Foundation 2020

Studies have established metabolic acidosis as a risk factor for progression of chronic kidney disease (CKD). There are few data on the association between metabolic acidosis ...

About Us

Editorial Policy

Advertising

eNewsletters

Contribute

Contact Us

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Small Cell Lung Cancer

Squamous Cell Lung Carcinoma

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

The Oncology Brothers

Rheumatology Rounds With Dr. Maheswaranathan

Healthcare Unfiltered

The Fellow on Call

Partners

Hurricanes & Health Care

Career Center

Expert Interviews

Subscribe